Surgical Science Sweden Crecimiento futuro
Future controles de criterios 4/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Surgical Science Sweden de 32.6% y 17.4% por año respectivamente. Se prevé que el BPA crezca en un 32.6% al año. Se espera que la rentabilidad financiera sea de 6.5% en 3 años.
Información clave
32.6%
Tasa de crecimiento de los beneficios
32.6%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Medical Equipment | 32.8% |
| Tasa de crecimiento de los ingresos | 17.4% |
| Rentabilidad financiera futura | 6.5% |
| Cobertura de analistas | Good |
| Última actualización | 30 Oct 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Surgical Science Sweden AB (publ) Just Missed EPS By 22%: Here's What Analysts Think Will Happen Next
Aug 25
Earnings Beat: Surgical Science Sweden AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Apr 21Results: Surgical Science Sweden AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts
Feb 24Recent updates
Surgical Science Sweden AB (publ) Just Missed EPS By 22%: Here's What Analysts Think Will Happen Next
Aug 25Earnings Beat: Surgical Science Sweden AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Apr 21Here's Why Surgical Science Sweden (STO:SUS) Has Caught The Eye Of Investors
Apr 16Surgical Science Sweden AB (publ)'s (STO:SUS) Share Price Is Still Matching Investor Opinion Despite 25% Slump
Mar 17Results: Surgical Science Sweden AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts
Feb 24Is There Now An Opportunity In Surgical Science Sweden AB (publ) (STO:SUS)?
Nov 29Should You Be Adding Surgical Science Sweden (STO:SUS) To Your Watchlist Today?
Oct 07Is Surgical Science Sweden AB (publ) (STO:SUS) Trading At A 39% Discount?
Aug 17With EPS Growth And More, Surgical Science Sweden (STO:SUS) Makes An Interesting Case
Jun 20A Look At The Fair Value Of Surgical Science Sweden AB (publ) (STO:SUS)
May 17Surgical Science Sweden AB (publ) (STO:SUS) Shares Could Be 49% Below Their Intrinsic Value Estimate
Dec 27Is Now The Time To Put Surgical Science Sweden (STO:SUS) On Your Watchlist?
Dec 06Is Now The Time To Look At Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Sep 08We Ran A Stock Scan For Earnings Growth And Surgical Science Sweden (STO:SUS) Passed With Ease
Aug 23Surgical Science Sweden AB (publ) (STO:SUS) Shares Slammed 33% But Getting In Cheap Might Be Difficult Regardless
May 26Here's Why We Think Surgical Science Sweden (STO:SUS) Is Well Worth Watching
Apr 29An Intrinsic Calculation For Surgical Science Sweden AB (publ) (STO:SUS) Suggests It's 44% Undervalued
Feb 20Is It Too Late To Consider Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Jan 11Does Surgical Science Sweden (STO:SUS) Deserve A Spot On Your Watchlist?
Dec 15Calculating The Intrinsic Value Of Surgical Science Sweden AB (publ) (STO:SUS)
Sep 16Is It Too Late To Consider Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Jul 05Calculating The Fair Value Of Surgical Science Sweden AB (publ) (STO:SUS)
Jun 08Is It Too Late To Consider Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Mar 23Calculating The Intrinsic Value Of Surgical Science Sweden AB (publ) (STO:SUS)
Mar 02Is Surgical Science Sweden AB (publ)'s (STO:SUS) Shareholder Ownership Skewed Towards Insiders?
Feb 09
Surgical Science Sweden AB (publ)'s (STO:SUS) Stock Is Going Strong: Have Financials A Role To Play?
Jan 01What Does Surgical Science Sweden AB (publ)'s (STO:SUS) Share Price Indicate?
Dec 14Does Surgical Science Sweden (STO:SUS) Deserve A Spot On Your Watchlist?
Nov 26Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2026 | 1,344 | 381 | 398 | 468 | 5 |
| 12/31/2025 | 1,111 | 257 | 251 | 308 | 6 |
| 12/31/2024 | 912 | 152 | 157 | 207 | 6 |
| 6/30/2024 | 838 | 198 | 100 | 151 | N/A |
| 3/31/2024 | 842 | 208 | 159 | 206 | N/A |
| 12/31/2023 | 883 | 234 | 194 | 238 | N/A |
| 9/30/2023 | 906 | 253 | 231 | 277 | N/A |
| 6/30/2023 | 901 | 234 | 194 | 234 | N/A |
| 3/31/2023 | 872 | 221 | 140 | 179 | N/A |
| 12/31/2022 | 803 | 188 | 95 | 129 | N/A |
| 9/30/2022 | 750 | 138 | 11 | 38 | N/A |
| 6/30/2022 | 640 | 124 | 61 | 80 | N/A |
| 3/31/2022 | 489 | 101 | 45 | 59 | N/A |
| 12/31/2021 | 367 | 86 | 25 | 39 | N/A |
| 9/30/2021 | 209 | 30 | 59 | 69 | N/A |
| 6/30/2021 | 138 | 21 | 17 | 26 | N/A |
| 3/31/2021 | 122 | 18 | 11 | 20 | N/A |
| 12/31/2020 | 105 | 16 | 15 | 23 | N/A |
| 9/30/2020 | 104 | 14 | 4 | 14 | N/A |
| 6/30/2020 | 112 | 19 | 42 | 54 | N/A |
| 3/31/2020 | 107 | 17 | 37 | 47 | N/A |
| 12/31/2019 | 102 | 13 | 46 | 55 | N/A |
| 9/30/2019 | 88 | 6 | 48 | 56 | N/A |
| 6/30/2019 | 70 | -5 | 6 | 12 | N/A |
| 3/31/2019 | 68 | -5 | 1 | 9 | N/A |
| 12/31/2018 | 66 | -5 | -2 | 7 | N/A |
| 9/30/2018 | 60 | -3 | 0 | 9 | N/A |
| 6/30/2018 | 57 | -6 | -9 | 0 | N/A |
| 3/31/2018 | 56 | -7 | N/A | 8 | N/A |
| 12/31/2017 | 57 | -3 | N/A | 7 | N/A |
| 9/30/2017 | 65 | 4 | N/A | 6 | N/A |
| 6/30/2017 | 60 | 3 | N/A | 12 | N/A |
| 3/31/2017 | 59 | 4 | N/A | 11 | N/A |
| 12/31/2016 | 58 | 3 | N/A | 13 | N/A |
| 12/31/2015 | 52 | 2 | N/A | 8 | N/A |
| 12/31/2014 | 41 | -3 | N/A | N/A | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (32.6% al año) de SUS es superior a la tasa de ahorro (1.1%).
Beneficios vs. Mercado: Se prevé que los beneficios (32.6% al año) de SUS crezcan más rápidamente que el mercado Swedish (15.7% al año).
Beneficios de alto crecimiento: Se espera que los beneficios de SUS crezcan significativamente en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (17.4% al año) de SUS crezcan más rápidamente que los del mercado Swedish (0.01% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 17.4% al año) de SUS crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de SUS sea baja dentro de 3 años (6.5%).